FR Ferreira

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE To assess the impact of omalizumab as an add-on therapy to standard treatment with inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA) on asthma-related quality of life (QoL) in patients with severe allergic asthma. METHODS This was a 20-week, randomized, open-label, study involving Brazilian patients (>12 years) with severe(More)
  • 1